STXS logo

STEREOTAXIS INC

STXSNYSE AMERICAN
πŸ† #3975 by market capEarnings Nov 10 Β· PostUS Equity
$0.91β–Ό $0.06 (βˆ’5.75%)
πŸŒ™ After hours$0.91β–Ό 0.49%Regular close Β· extended-hours price shown
πŸ””
Track STXS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.8%
7dβ–Ό 7.7%
14dβ–Ό 13.3%
30dβ–Ό 27.4%
ytdβ–Ό 60.2%
1yβ–Ό 68.7%
🏦Market Cap
$92M
Small Cap
πŸ“ˆRevenue Growth (YoY)
20.3%
Healthy
πŸ“ŠGross Margin
55.6%
Healthy
πŸ’΅FCF Margin
-51.6%
Thin
βš–οΈP/S Ratio
3.3x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.91 – $1.00
52-Week Range
$0.95 – $3.04
Volume (shares)
779,415
Avg Volume (shares)
β€”
Shares Outstanding
100.2M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
$32M
Last Q Revenue
$8M
P/E Ratio
-4.0
P/S Ratio
3.3x
EPS (TTM)
$-0.22
Dividend Yield
0.00%
Dilution (1yr)
+10.5%
STXS logo

STEREOTAXIS INC

STXS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$32Mβ–² +20.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
52.7%β–Ό βˆ’2.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$22Mβ–Ό βˆ’10.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$14Mβ–² +61.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
96.0Mβ–² +10.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8Mβ–² +$2M YoY
StockOtter Β· stockotter.space

About STEREOTAXIS INC

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

GlobeNewsWireΒ·7d ago

Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia

ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņő Clinical Unive

GlobeNewsWireΒ·9d ago

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financi

GlobeNewsWireΒ·Sep 16

Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026

New digital technologies, including Synchrony and SynX, will be featured at HRX Stereotaxis CEO to join main-stage panel on Autonomous EP Systems ST. LOUIS, Sept.

GlobeNewsWireΒ·Sep 3

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Electrophysiology team a

Seeking AlphaΒ·Aug 11

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

MarketBeatΒ·Aug 11

Stereotaxis Q2 Earnings Call Highlights

Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and